Measure of Acceptance of chRonic Visible sKin conditionS
Launched by UNIVERSITY HOSPITAL, TOURS · Oct 24, 2023
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how people feel about living with visible chronic skin conditions, such as port wine stains, alopecia areata, vitiligo, and hyperpigmentation. The goal is to test four different questionnaires that will help researchers learn more about patients' acceptance of these conditions and how it affects their mental well-being and social interactions. The study will include a wide range of participants, including children as young as six, adults, and their parents, to ensure that the findings reflect different experiences and perspectives.
To participate, individuals need to have one of the specified skin conditions, and they must be open to sharing their experiences. Parents of affected children or young adults living at home are also welcome to join. Participants will be asked to complete the questionnaires, which will help researchers gather valuable information about the emotional and social impacts of these skin conditions. It's important to note that people with certain other skin issues or significant psychiatric disorders will not be eligible for this study. This trial is currently recruiting participants, and being part of it could help improve understanding and support for those living with visible skin conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- 1. Targeted pathologies:
- • Flat angioma
- • Primary hypopigmentation and early vitiligo
- • Primary hyperpigmentation
- • Refractory alopecia areata or congenital alopecia
- 2. Persons concerned:
- • Children (≥ 6 years old) suffering from one of the aforementioned pathologies
- • Adults suffering from one of the above-mentioned pathologies
- • Parents of children suffering from one of the aforementioned pathologies
- • Parents of young adult patients if they live under the same roof
- • 3. Oral agreement for each person (major/minor) and, where applicable, one of the holders of parental authority (minor)
- Exclusion Criteria:
- • 1. Secondary "marks" (post-inflammatory, post-medication, post-traumatic, etc.)
- • 2. Major psychiatric disorders
About University Hospital, Tours
The University Hospital of Tours, a leading academic medical institution in France, is dedicated to advancing healthcare through innovative clinical research and patient-centered care. With a strong emphasis on collaboration between researchers, clinicians, and community partners, the hospital fosters a dynamic environment for conducting high-quality clinical trials across various medical disciplines. Its commitment to excellence in patient safety, ethical standards, and scientific integrity positions the University Hospital of Tours as a pivotal contributor to the development of new therapies and health solutions, ultimately enhancing patient outcomes and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tours, , France
Patients applied
Trial Officials
Annabel MARUANI, MD-PhD
Study Director
University Hospital of TOURS
Jean-Benoit HARDOUIN, MD-PhD
Study Chair
INSERM UMR 1246 SPHERE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported